Healthcare News
Articles, Jobs and Consultants for the Healthcare Professional
Home      View Jobs     Post Jobs     Library     Advertise     Plan Financials     About     Subscribe     Contact    

Drugmakers Master Rolling Out Their Own Generics To Stifle Competition

First few Article Sentences

When PDL BioPharma's $40 million blood-pressure medicine faced the threat of a generic rival this year, the company pulled out a little-known strategy that critics say helps keep drugs expensive and competition weak.

It launched its own generic version of Tekturna, a pill taken daily by thousands. PDL's "authorized" copycat hit the market in March, stealing momentum from the new rival and protecting sales even though Tekturna's patent ran out last year.

PDL's version sold for $187 a month versus $166 for the competing generic, made by Anchen Pharmaceuticals, according to Connecture, an information technology firm. PDL's brand-name Tekturna runs about $208 a month.


Hancock, Jay

Lupkin, Sydney

Kaiser Health News

Prescription Drugs

August 6, 2019

back to library